Arverapamil

DB06669InvestigationalSmall molecule

Investigated for use/treatment in irritable bowel syndrome (IBS) and diarrhea.

Chemical structure of Arverapamil
Primary indication
Investigated for use/treatment in irritable bowel syndrome (IBS) and diarrhea.Curator reviewed
Formula / weight
C26H36N2O4 · 440.584 g/mol (avg)
Also known as
(R)-norverapamil
Code names
AGI-003

Resolves to

Compound
UNII3J8P56R04PCAS123932-43-4ChEBI134082
Structure
InChIKeyUPKQNCPKPOLASS-AREMUKBSSA-NSMILESCOC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC

What you can answer from here — as of June 12, 2020

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Arverapamil, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In